ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with (89)Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol

BACKGROUND: ImmunoPET is a multicentre, single arm, phase 0–1 study that aims to establish if (89)Zr-durvalumab PET/CT can be used to interrogate the expression of PD-L1 in larger, multicentre clinical trials. METHODS: The phase 0 study recruited 5 PD-L1+ patients with metastatic non-small cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegi-Johnson, Fiona, Rudd, Stacey E, Wichmann, Christian, Akhurst, Tim, Roselt, Peter, Trinh, Jenny, John, Thomas, Devereux, Lisa, Donnelly, Paul S, Hicks, Rod, Scott, Andrew M, Steinfort, Daniel, Fox, Stephen, Blyth, Benjamin, Parakh, Sagun, Hanna, Gerard G, Callahan, Jason, Burbury, Kate, MacManus, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677006/
https://www.ncbi.nlm.nih.gov/pubmed/36400733
http://dx.doi.org/10.1136/bmjopen-2021-056708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677006/
https://www.ncbi.nlm.nih.gov/pubmed/36400733
http://dx.doi.org/10.1136/bmjopen-2021-056708

Ejemplares similares